PCF study finds that adding a 22-gene test to standard prostate cancer risk groups improves accuracy of patient prognosis

Prostate Cancer Foundation| Fri Jun 09 16:13:25 EDT 2017
PCF study finds that adding a 22-gene test to standard prostate cancer risk groups improves accuracy of patient prognosis

A PCF study presented at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that using a 22-gene test along with standard prostate cancer risk group features vastly improves predictions of how aggressive a patient’s cancer is – enabling clinicians to choose more appropriate therapies and better avoid over or under-treatment.

Prostate cancer is a highly variable disease.  Some patients have very aggressive cancer that requires aggressive treatment, while in ....

Read at Source
Related News